BRPI0413565B8 - análogos de quinazolina como inibidores de receptor de erbb2, seu uso e sua composição farmacêutica - Google Patents

análogos de quinazolina como inibidores de receptor de erbb2, seu uso e sua composição farmacêutica

Info

Publication number
BRPI0413565B8
BRPI0413565B8 BRPI0413565A BRPI0413565A BRPI0413565B8 BR PI0413565 B8 BRPI0413565 B8 BR PI0413565B8 BR PI0413565 A BRPI0413565 A BR PI0413565A BR PI0413565 A BRPI0413565 A BR PI0413565A BR PI0413565 B8 BRPI0413565 B8 BR PI0413565B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
receptor inhibitors
erbb2 receptor
quinazoline analogues
analogues
Prior art date
Application number
BRPI0413565A
Other languages
English (en)
Inventor
Buckmelter Alexandre
Wallace Eli
Topalov George
Lyssikatos Joseph
Zhao Qian
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/642,440 external-priority patent/US7501427B2/en
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of BRPI0413565A publication Critical patent/BRPI0413565A/pt
Publication of BRPI0413565B1 publication Critical patent/BRPI0413565B1/pt
Publication of BRPI0413565B8 publication Critical patent/BRPI0413565B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

análogos de quinazolina como inibidores de receptor de tirosina quinase. essa invenção fornece análogos de quinazolina de fórmula (i): onde a é ligado a pelo menos um dos carbonos na posição 5, 6, 7 ou 8 do anel bicíclico, e o anel é substituído por até dois grupos r 3 independentes. a invenção também inclui métodos de uso de compostos de fórmula (i) como inibidores de receptor de tirosina quinase tipo i e para o tratamento de doenças hiperproliferativas como câncer.
BRPI0413565A 2003-08-14 2004-08-10 análogos de quinazolina como inibidores de receptor de erbb2, seu uso e sua composição farmacêutica BRPI0413565B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/642,440 US7501427B2 (en) 2003-08-14 2003-08-14 Quinazoline analogs as receptor tyrosine kinase inhibitors
US10/642.440 2003-08-14
US55171804P 2004-03-10 2004-03-10
US60/551.718 2004-03-10
PCT/US2004/026235 WO2005016346A1 (en) 2003-08-14 2004-08-10 Quinazoline analogs as receptor tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
BRPI0413565A BRPI0413565A (pt) 2006-10-17
BRPI0413565B1 BRPI0413565B1 (pt) 2019-10-01
BRPI0413565B8 true BRPI0413565B8 (pt) 2021-05-25

Family

ID=34198338

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413565A BRPI0413565B8 (pt) 2003-08-14 2004-08-10 análogos de quinazolina como inibidores de receptor de erbb2, seu uso e sua composição farmacêutica

Country Status (24)

Country Link
US (2) US7452895B2 (pt)
EP (1) EP1660090B1 (pt)
JP (1) JP4828421B2 (pt)
KR (2) KR101028952B1 (pt)
CN (3) CN103664802B (pt)
AR (1) AR045378A1 (pt)
AU (1) AU2004264937B2 (pt)
BR (1) BRPI0413565B8 (pt)
CA (1) CA2535614C (pt)
CL (1) CL2004002066A1 (pt)
CY (1) CY1113992T1 (pt)
DK (1) DK1660090T3 (pt)
ES (1) ES2399427T3 (pt)
HK (1) HK1085400A1 (pt)
IL (1) IL173593A (pt)
IS (1) IS8288A (pt)
MX (1) MXPA06001767A (pt)
NO (1) NO336275B1 (pt)
NZ (1) NZ545459A (pt)
PL (1) PL1660090T3 (pt)
PT (1) PT1660090E (pt)
RU (1) RU2350605C2 (pt)
TW (1) TWI353982B (pt)
WO (1) WO2005016346A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CN103664802B (zh) * 2003-08-14 2015-08-05 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
ES2335535T3 (es) * 2005-11-15 2010-03-29 Array Biopharma Inc. Derivados de n4-fenil-quinazolin-4-amina ycompuestos afines como inhibidores de la tirosina quinasa receptora erbb tipo i para el tratamiento de enfermedades hiperproliferativas.
CN104011047A (zh) 2011-10-14 2014-08-27 阵列生物制药公司 选择性herb2抑制剂arry-380的多晶型物和含有它们的药物组合物
HUE035247T2 (hu) 2011-10-14 2018-05-02 Array Biopharma Inc Szilárd diszperzió
JP2015514075A (ja) 2012-03-23 2015-05-18 アレイ バイオファーマ、インコーポレイテッド 脳癌の治療
JP2018535923A (ja) * 2015-09-04 2018-12-06 アスラン ファーマシューティカルズ ピーティーイー リミテッド 胆道癌の治療
US20190134034A1 (en) * 2016-04-21 2019-05-09 Aslan Pharmaceuticals Pte. Ltd. Method of Treating Liver Cancer
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
CN106317040A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106349230A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN106349231A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106317039A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106279135A (zh) * 2016-08-09 2017-01-04 浙江医药高等专科学校 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
SG10201913858WA (en) 2016-08-26 2020-03-30 Agency Science Tech & Res Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
EP3589286B1 (en) 2017-03-02 2022-08-03 ASLAN Pharmaceuticals Pte Ltd Dhodh inhibitor for treating haematological cancer
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
WO2018222135A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
WO2018222134A1 (en) 2017-06-02 2018-12-06 Aslan Pharmaceuticals Pte Ltd Cancer therapy
PT3853220T (pt) 2018-09-18 2024-02-22 Hoffmann La Roche Derivados de quinazolina enquanto agentes antitumorais
CN112969699A (zh) * 2018-10-09 2021-06-15 亚狮康私人有限公司 瓦利替尼的丙二酸盐
CN111499622B (zh) * 2019-07-08 2023-06-06 山东省科学院菏泽分院 一种治疗胆管癌的药物的制备方法
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
TW202345816A (zh) * 2022-03-28 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類化合物、其製備方法及其在醫藥上的應用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583774A (en) 1948-04-30 1952-01-29 Merck & Co Inc Vitamin b6 derivatives
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US5204348A (en) * 1988-10-06 1993-04-20 Mitsui Toatsu Chemicals Inc. Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components
CA1340821C (en) 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (pt) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ332119A (en) 1996-04-12 2001-08-31 Warner Lambert Co Quinazoline compounds which are irreversible inhibitors of tyrosine kinases
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
CZ20001709A3 (cs) 1997-11-11 2001-12-12 Pfizer Products Inc. Deriváty thienopyrimidu a thienopyridinu, farmaceutické kompozice a způsoby léčení na jejich bázi
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス，インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
US6017922A (en) 1998-05-18 2000-01-25 U.S. Bioscience, Inc. Thermally stable trimetrexates and processes for producing the same
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
GEP20032922B (en) 1999-01-13 2003-03-25 Warner Lambert Co Benzoheterocycles and Their Use as MEK Inhibitors
EP1154774B1 (en) * 1999-02-10 2005-06-22 AstraZeneca AB Quinazoline derivatives as angiogenesis inhibitors
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
KR20020032608A (ko) 1999-09-21 2002-05-03 다비드 에 질레스 퀴나졸린 화합물 및 이를 함유하는 제약 조성물
AU3092901A (en) 2000-02-17 2001-08-27 Bristol Myers Squibb Co Aniline-derived ligands for the thyroid receptor
TR200402656T4 (tr) 2000-06-06 2004-11-22 Pfizer Products Inc. Antikanser ajanları olarak faydalı tiyofen türevleri
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
CZ299561B6 (cs) * 2000-06-30 2008-09-03 Glaxo Group Limited Chinazolinaminový derivát a farmaceutický prostredek
US7265134B2 (en) 2001-08-17 2007-09-04 Merck & Co., Inc. Tyrosine kinase inhibitors
US7169788B2 (en) 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
CA2465068A1 (en) * 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
PT1463506E (pt) * 2001-12-24 2009-12-10 Astrazeneca Ab Derivados de quinazolina substituídos como inibidores de aurora cinases
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CA2514479A1 (en) 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
PE20040945A1 (es) 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
CA2527017A1 (en) 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN103664802B (zh) 2003-08-14 2015-08-05 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
EP1658080A1 (en) 2003-08-18 2006-05-24 Pfizer Products Inc. Dosing schedule for a erbb2 anticancer agents
MXPA06005024A (es) 2003-11-06 2006-07-06 Pfizer Prod Inc Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer.
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
ES2335535T3 (es) 2005-11-15 2010-03-29 Array Biopharma Inc. Derivados de n4-fenil-quinazolin-4-amina ycompuestos afines como inhibidores de la tirosina quinasa receptora erbb tipo i para el tratamiento de enfermedades hiperproliferativas.

Also Published As

Publication number Publication date
RU2350605C2 (ru) 2009-03-27
CN103664802B (zh) 2015-08-05
CN102432552A (zh) 2012-05-02
KR20100018079A (ko) 2010-02-16
AU2004264937A1 (en) 2005-02-24
CA2535614C (en) 2009-12-22
IL173593A0 (en) 2006-07-05
JP4828421B2 (ja) 2011-11-30
DK1660090T3 (da) 2012-12-17
TW200519096A (en) 2005-06-16
US7452895B2 (en) 2008-11-18
RU2006103493A (ru) 2007-09-20
BRPI0413565B1 (pt) 2019-10-01
US8278314B2 (en) 2012-10-02
IS8288A (is) 2006-02-07
KR101028952B1 (ko) 2011-04-12
AU2004264937B2 (en) 2010-04-29
CN103664802A (zh) 2014-03-26
PL1660090T3 (pl) 2013-04-30
TWI353982B (en) 2011-12-11
ES2399427T3 (es) 2013-04-01
HK1085400A1 (en) 2006-08-25
CN103772373B (zh) 2017-06-09
BRPI0413565A (pt) 2006-10-17
NZ545459A (en) 2009-12-24
CN103772373A (zh) 2014-05-07
KR100953246B1 (ko) 2010-04-16
NO336275B1 (no) 2015-07-06
KR20060064630A (ko) 2006-06-13
CY1113992T1 (el) 2016-07-27
NO20061171L (no) 2006-04-10
IL173593A (en) 2011-11-30
JP2007502295A (ja) 2007-02-08
US20090048279A1 (en) 2009-02-19
CL2004002066A1 (es) 2005-06-03
CN102432552B (zh) 2016-01-20
EP1660090A1 (en) 2006-05-31
US20050043334A1 (en) 2005-02-24
EP1660090B1 (en) 2012-11-21
WO2005016346A1 (en) 2005-02-24
AR045378A1 (es) 2005-10-26
PT1660090E (pt) 2013-01-11
MXPA06001767A (es) 2006-05-12
CA2535614A1 (en) 2005-02-24
EP1660090A4 (en) 2008-12-03

Similar Documents

Publication Publication Date Title
BRPI0413565B8 (pt) análogos de quinazolina como inibidores de receptor de erbb2, seu uso e sua composição farmacêutica
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
ECSP056072A (es) Pirimidinonas sustituidas
BR0316152A (pt) Compostos de pirimidina
PE20050081A1 (es) Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
BRPI0607796A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
EA200401194A1 (ru) Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение
ECSP055858A (es) 2-(1h-indazol-6-ilamino)-compuestos benzamidas como inhibidores de la proteinquinasas útiles para el tratamiento de enfermedades oftálmicas
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
BRPI0407827A (pt) compostos de aminoeteroarila como inibidores de proteìna cinase
BRPI0414489A8 (pt) derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina
BRPI0510095A (pt) tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
EA200801011A1 (ru) Производные пиразина как модуляторы натриевых каналов для лечения боли
ECSP078062A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/51, 31/517, 31/535; C07D 403/00, 239/82; A61P 35/00

Ipc: A61K 31/51 (2011.01), A61K 31/517 (2011.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF